One of the most widely watched names in the healthcare sector is Hims & Hers Health Inc. (NYSE: HIMS), not only due to its ...

Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the ...

According to Benzinga Pro, Hims & Hers Health's peer group average for short interest as a percentage of float is 8.31%, which means the company has more short interest than most of its peers. Did you ...

Hims & Hers Health ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the ...

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 25, 2025 to file lead plaintiff applications in securities ...

Rachel Sacks is a freelance writer and copywriter with over 10 years of experience writing about health and wellness, ...

Law Offices of Howard G. Smith continues its investigation on behalf of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) investors concerning the Company's possible violations of federal ...

The Law Offices of Frank R. Cruz continues its investigation of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) on behalf of investors concerning the Company's possible violations of ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Shares of Hims & Hers, which has clashed with Novo Nordisk over its sales of compounded glucagon-like peptide inhibitors, rose slightly in the wake of the report, and have more than doubled in value ...